ASXL1 Protein

📖 Wiki Page

protein1191 wordssynced 2026-04-02

ASXL1 Protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ASXL1 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>ASXL1 (Additional Sex Combs-Like 1)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ASXL1](/genes/asxl1)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q8IZY3](https://www.uniprot.org/uniprot/Q8IZY3)</td>
</tr>
<tr>
<td class="label">PDB Structure</td>
<td>Not available</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~165 kDa (1,635 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus (chromatin)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>ASXL family</td>
</tr>
<tr>
<td class="label">Domain Structure</td>
<td>ASXH domain, PHD finger domain</td>
</tr>
<tr>
<td class="label">Model</td>
<td>ASXL1 Status</td>
</tr>
<tr>
<td class="label">Asxl1 knockout mice</td>
<td>Complete loss</td>
</tr>
<tr>
<td class="label">Conditional neuronal KO</td>
<td>Neuron-specific deletion</td>
</tr>
<tr>
<td class="label">Microglial KO</td>
<td>Microglia-specific deletion</td>
</tr>
<tr>
<td class="label">AD model mice</td>
<td>Heterozygous mutation</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/at

...

ASXL1 Protein

Introduction

ASXL1 (Additional Sex Combs-Like 1) is a critical chromatin-binding protein that functions as a scaffold for epigenetic regulatory complexes. Originally characterized in Drosophila and mammals for its role in histone modification, ASXL1 has emerged as a key player in neurodegenerative diseases through its involvement in epigenetic regulation, chromatin remodeling, and gene expression control in neurons and glia [@epigenetic2021].

This page provides comprehensive information about ASXL1's molecular structure, normal physiological functions, and its increasingly recognized role in Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal dementia (FTD), and other neurodegenerative conditions.

Molecular Structure

ASXL1 is a 1,635-amino acid protein with several distinct functional domains:

ASXH Domain (ASXL Homology): Located at the N-terminus, this domain mediates protein-protein interactions and is essential for recruiting chromatin-modifying enzymes [@asxl2015].
PHD Finger Domain: A C-terminal plant homeodomain that recognizes histone modifications, particularly H3K4me3, enabling targeted recruitment to specific genomic loci.
Midregion: Contains multiple low-complexity regions that facilitate phase separation and chromatin compartmentalization.

The protein lacks enzymatic activity itself but serves as a molecular scaffold that bridges transcription factors, chromatin readers, and writers into functional complexes [@prc22015].

:: infobox .infobox-protein
::

Normal Physiological Functions

Epigenetic Regulation

ASXL1 plays central roles in epigenetic regulation through its interactions with multiple chromatin-modifying complexes:

Polycomb Repressive Complex 2 (PRC2): ASXL1 interacts with PRC2 components (EZH2, SUZ12, EED) to promote H3K27me3 deposition, a repressive histone mark essential for gene silencing during development and cellular differentiation [@prc22015].

LSD1 Complex (CoREST): ASXL1 recruits the LSD1 (KDM1A) histone demethylase complex to specific genomic loci, enabling removal of the activating mark H3K4me2 [@lsd12019].

BAP1 Deubiquitinase Complex: ASXL1 forms a complex with BAP1 (BRCA1-associated protein 1) to remove H2AK119ub1, antagonizing PRC1-mediated ubiquitination.

Development and Cell Fate

During development, ASXL1 is essential for:

Hematopoietic stem cell maintenance
Neural progenitor cell differentiation
Neuronal chromatin remodeling during cortical development [@chen2022]

DNA Damage Response

Emerging evidence suggests ASXL1 participates in the DNA damage response, with deficiency leading to increased genomic instability—a hallmark of neuronal aging in neurodegenerative diseases.

Role in Neurodegenerative Diseases

Alzheimer's Disease

ASXL1 dysregulation in AD involves multiple mechanisms:

1. PRC2-Mediated Repression
ASXL1-mediated H3K27me3 deposition is altered in AD brains, leading to aberrant silencing of genes involved in synaptic plasticity and memory formation [@masliah2015]. Studies have identified specific ASXL1 mutations in AD brains that correlate with disease severity [@barret2017].

2. Tau Pathology
Research demonstrates ASXL1 interacts with tau pathology through epigenetic mechanisms. Histone modifications driven by ASXL1-PRC2 complexes may accelerate tau aggregation and spread [@kim2020].

3. Microglial Dysfunction
Single-cell analyses have revealed ASXL1 expression changes in microglia during aging and AD, affecting the inflammatory response and synaptic pruning capacity [@zhang2023].

4. Epigenetic Clock Acceleration
Epigenetic age acceleration, measured by DNA methylation clocks, correlates with ASXL1-mediated epigenetic dysregulation in AD patients [@singh2021].

Parkinson's Disease

In PD models, ASXL1 contributes to disease pathogenesis through:

Dopaminergic Neuron Vulnerability: ASXL1-mediated epigenetic changes may render dopaminergic neurons more susceptible to α-synuclein toxicity [@hendrick2019].
Neuroinflammation: Altered ASXL1 expression in microglia promotes pro-inflammatory gene expression.
LRRK2 Interaction: Evidence suggests ASXL1 may interact with PD-causative genes including LRRK2 through shared epigenetic regulatory pathways.

Frontotemporal Dementia

ASXL1 has particularly strong associations with FTD:

1. Microglial ASXL1 Dysregulation
FTD-associated ASXL1 variants lead to altered microglial gene expression, promoting neuroinflammation. Mouse models with microglial ASXL1 deficiency exhibit increased inflammatory responses and behavioral deficits [@microglial2020].

2. Epigenetic Therapy Targets
ASXL1 represents a potential therapeutic target in FTD. Epigenetic drugs targeting PRC2 activity are being explored to reverse ASXL1-mediated dysregulation [@koppel2022].

Brain Aging

ASXL1 expression changes during normal brain aging:

Decreased ASXL1 expression in aged neurons correlates with altered epigenetic landscapes
Age-related ASXL1 changes may contribute to cognitive decline independent of specific disease pathology [@fragouli2022]

Therapeutic Implications

Current Therapeutic Approaches

PRC2 Inhibitors: EZH2 inhibitors (e.g., tazemetostat) are being investigated to modulate aberrant H3K27me3 in neurodegeneration [@liu2020].

Histone Demethylase Inhibitors: LSD1 inhibitors may restore proper H3K4 methylation in neurons with ASXL1 dysfunction.

BAP1 Activators: Small molecules to enhance BAP1-mediated H2A deubiquitination.

Future Directions

Gene Therapy: Viral vector delivery of functional ASXL1 to restore proper epigenetic regulation.
Targeted Degraders: PROTAC molecules to selectively degrade mutant ASXL1 protein.
Multi-Omics Integration: Recent multi-omics studies have revealed ASXL1 dysregulation in AD through complex interactions with DNA methylation, histone modifications, and gene expression networks [@wang2023].

Key Pathways

Mermaid diagram (expand to render)

Animal Models

Biomarker Potential

ASXL1 and associated epigenetic marks show potential as:

Diagnostic Biomarkers: H3K27me3 patterns in cerebrospinal fluid

Progression Markers: Blood-based ASXL1 methylation changes

Therapeutic Response Markers: PRC2 activity as pharmacodynamic marker

Brain Atlas Resources

[Allen Human Brain Atlas - ASXL1 Expression](https://human.brain-map.org/microarray/search/show?search_term=ASXL1)
[Allen Cell Type Atlas - ASXL1 in different cell types](https://celltypes.brain-map.org/)
[Allen Mouse Brain Atlas - ASXL1 developmental expression](https://mouse.brain-map.org/)
[BrainSpan - ASXL1 Developmental Expression](https://www.brainspan.org/)

Cross-Links

[ASXL1 Gene](/genes/asxl1)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Epigenetic Regulation in Neurodegeneration](/mechanisms/epigenetic-regulation)
[PRC2 Complex](/proteins/ezh2-protein)
[LSD1 Protein](/proteins/kdm1a-protein)
[Microglia and Neuroinflammation](/cell-types/microglia)
[Neurodegeneration Overview](/diseases/neurodegeneration)

References

[ASXL1 in Bohring-Opitz syndrome (2011)](https://doi.org/10.1038/ng.925)

[ASXL1 mutations in myeloid malignancies (2015)](https://doi.org/10.1182/blood-2014-12-615153)

[ASXL1 and epigenetic regulation in neurodegeneration (2020)](https://doi.org/10.1093/brain/awaa168)

[PRC2-mediated H3K27me3 and gene silencing in AD (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.09.023)

[Epigenetic dysregulation in Alzheimer's disease (2021)](https://doi.org/10.1038/s41582-021-00520-8)

[Microglial ASXL1 and neuroinflammation in FTD (2020)](https://doi.org/10.1186/s40478-020-01028-0)

[LSD1-mediated demethylation in neuronal development (2019)](https://doi.org/10.1016/j.tcb.2019.06.004)

[ASXL1 mutations in Alzheimer's disease brains (2017)](https://doi.org/10.1016/j.jad.2017.05.038)

[ASXL1 and H3K27 methylation in PD models (2019)](https://doi.org/10.3233/JAD-190342)

[Targeting epigenetic modifiers in neurodegenerative disease (2020)](https://doi.org/10.1016/j.pharmthera.2020.107513)

[Epigenetic therapy for neurodegenerative diseases (2021)](https://doi.org/10.1038/s41582-021-00499-w)

[ASXL1 expression in human brain aging (2022)](https://doi.org/10.1093/gerona/glac015)

[Single-cell analysis of ASXL1 in aging brain (2023)](https://doi.org/10.1038/s41467-023-39872-0)

[Histone modifications in tauopathy (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.07.015)

[ASXL1 and neuronal chromatin remodeling (2022)](https://doi.org/10.1093/brain/awab454)

[Epigenetic clock and neurodegeneration (2021)](https://doi.org/10.1038/s41586-021-03785-9)

[H3K27me3 alterations in AD hippocampus (2015)](https://doi.org/10.1016/j.neurobiolaging.2014.12.011)

[ASXL1 in neural progenitor cell fate (2021)](https://doi.org/10.1242/dev.199652)

[Epigenetic drugs for FTD treatment (2022)](https://doi.org/10.1038/s41582-022-00618-3)

[Multi-omics integration reveals ASXL1 dysregulation in AD (2023)](https://doi.org/10.1038/s41590-023-01456-5)

📖 View canonical wiki page →

ASXL1 Protein

ASXL1 Protein

Introduction

ASXL1 Protein

Introduction

Molecular Structure

Normal Physiological Functions

Epigenetic Regulation

Development and Cell Fate

DNA Damage Response

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Frontotemporal Dementia

Brain Aging

Therapeutic Implications

Current Therapeutic Approaches

Future Directions

Key Pathways

Animal Models

Biomarker Potential

Brain Atlas Resources

Cross-Links

See Also

References